LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biosensor-Based Rapid Urine Test Detects Urogenital Schistosomiasis

By LabMedica International staff writers
Posted on 14 Jul 2015
Print article
Image: Egg of Schistosoma haematobium in a wet mount of urine concentrates, showing the characteristic terminal spine (Photo courtesy of Centers for Disease Control and Prevention).
Image: Egg of Schistosoma haematobium in a wet mount of urine concentrates, showing the characteristic terminal spine (Photo courtesy of Centers for Disease Control and Prevention).
In infrastructure-limited regions, point-of-care (POC) molecular diagnostics hold the potential to transform the management of infectious diseases such as schistosomiasis that carry significant long-term morbidity if left undiagnosed.

Electrochemical biosensors are well suited for molecular diagnostics because of their high sensitivity, low cost, ease of integration into POC devices, and portability of the reader instrumentation and have now been used to detect urogenital schistosomiasis.

Scientists at Stanford University School of Medicine (CA, USA) and their colleagues have developed a strategy for a rapid one hour molecular diagnosis of bacterial urinary tract infections using electrochemical biosensors. Urinary cells are lysed and directly applied to an array of sensors functionalized with oligonucleotide probes targeting the 16S ribosomal ribonucleic acid (rRNA) of common uropathogens. Formation of the sequence-specific hybridization complex between the pathogen rRNA and the labeled capture and detector probe pairs is detected by an enzyme tag that mediates an amperometric signal output.

The biosensor is composed of three planar gold electrodes, one each for working, auxiliary, and reference. For the biosensor assay, capture probes are bound to the surface of the working electrode via a thiol linkage. Cells in the sample are lysed and mixed with a buffered solution of detector probe, then applied to the sensor surface. If the target rRNA is present, a hybridization complex of target, capture, and detector probes forms. This complex is detected by binding of horseradish peroxidase (HRP)-conjugated anti-fluorescein binding to a fluorescein tag on the detector probe and addition of tetramethylbenzidine (TMB) substrate. The electron transport mediated by the HRP is measured amperometerically, and the signal is proportional to the quantity of the target.

By inducing bulk fluid motion and local heating, alternating current (AC) electrokinetics improved overall signal-to-noise of the biosensor assay. Further implementation of electrokinetics will facilitate integration into a POC device as it obviates the need for an external incubator for hybridization. For schistosomal detection, the scientists applied square wave AC potential across the working and auxiliary electrodes of the electrochemical sensors using a function generator.

The authors concluded that they have made an important step toward development of a POC device for rapid detection of Schistosoma haematobium eggs in urine. They have implemented strategies that will aid in device integration, such as mechanical lysis and AC electrokinetics. For future development, they will integrate this core assay into a fully automated microfluidics cartridge, further optimize the detection sensitivity, and validate with clinical samples.

Related Links:

Stanford University School of Medicine



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
H.pylori Test
Humasis H.pylori Card
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.